![Barry Simon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barry Simon
Direktör/Styrelseledamot på
IMMUNITYBIO, INC.
Förmögenhet: 21 M $ per 2026-05-31
Profil
Barry J.
Simon currently works at Brink Biologics, Inc., as Chief Executive Officer from 2015, Coneksis, Inc., as Chief Executive Officer from 2015, and ImmunityBio, Inc., as Director & Chief Corporate Affairs Officer from 2021.
Dr. Simon also formerly worked at NantKwest, Inc., as President, Director & Chief Administrative Officer from 2017 to 2021, Cue Biopharma, Inc., as Independent Director, Viracta Subsidiary, Inc., as Director from 2017 to 2020, Viracta Therapeutics, Inc., as Independent Director from 2021 to 2024, Immunomedics, Inc., as Vice President, Roche Holding AG, as Vice President, iTherX Pharmaceuticals, Inc., as Vice President-Clinical & Regulatory Affairs, Connetics Corp., as Vice President, Roche Diagnostics Corp., as Vice President from 1997 to 2004, HealthPro BioVentures LLC, as Vice President, North Sound Capital LLC, as Vice President, and Roche Labs, as Vice President.
Dr. Simon received his doctorate degree in 1990 from State University of New York at Downstate Medical Center.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IMMUNITYBIO INC 0,27 % | 2026-06-04 | 2 827 788 ( 0,27 % ) | 21 M $ | 2026-05-31 |
Aktiva positioner av Barry Simon
| Företag | Position | Start |
|---|---|---|
| IMMUNITYBIO, INC. | Direktör/Styrelseledamot | 2007-01-01 |
Brink Biologics, Inc.
 Brink Biologics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Verkställande Direktör | 2015-03-01 |
Tidigare kända positioner av Barry Simon
| Företag | Position | Slut |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2024-12-18 |
| CUE BIOPHARMA, INC. | Ordförande | - |
| IMMUNITYBIO, INC. | Verkställande Direktör | 2015-03-01 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Direktör/Styrelseledamot | 2020-11-01 |
Roche Diagnostics Corp.
 Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Develops and produces medical tests and digital tools | Företagsledare/Principal | 2004-12-01 |
Barry Simons utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
48
Första gradens relationer
15
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 15 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services Engages in the discovery and development of drugs and therapies | Distribution Services |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Develops and commercializes dermatology products | Health Technology |
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology Develops and produces cancer treatment products | Health Technology |
Roche Diagnostics Corp.
Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Develops and produces medical tests and digital tools | Health Technology |
HealthPro BioVentures LLC
 HealthPro BioVentures LLC Investment ManagersFinance HealthPro BioVentures serves the biotechnology, biomedical, healthcare and pharmaceutical sectors. Their purpose is to define, enhance and realize value for their clients by leveraging their experience, resources and network of relationships. The firm seeks to provide unparalleled services to meet the needs of the life sciences sector, from large corporate entities to emerging companies. HealthPro originally emerged from DavosPharma. They draw on extensive contacts through their relationships and association with DavosPharma. As a result, HealthPro has a network of both buy-side and sell-side healthcare opportunities. HealthPro BioVentures' services include the development of strategic and tactical themes and target lists of potential partners, access to their vast, proprietary library of available compounds, assisting with presentations and due diligence dossiers, analysis of the synergies of potential strategic partners, advising on structure, timing and pricing of transactions and assisting with negotiation, documentation and closing of transactions. HealthPro targets potential partners and investors to assist both public and private companies who are looking to acquire a strategic target company or product. The firm's portfolio of services allows them to represent life sciences companies that are either interested in being acquired or interested in investing specific assets. In both by-side and sell-side transactions, their focus is on developing transactions that are mutually beneficial to both the buyer and the seller. | Finance |
State University of New York at Downstate Medical Center
 State University of New York at Downstate Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
North Sound Capital LLC
 North Sound Capital LLC Investment ManagersFinance North Sound is a global long/short equity hedge fund manager. Though not limited by sector, they tend to focus on large-cap companies in the finance, communications, retail, energy and consumer services sectors. | Finance |
Cue Biopharma, Inc.
 Cue Biopharma, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Health Technology |
Brink Biologics, Inc.
Brink Biologics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
ImmunityBio, Inc.
 ImmunityBio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for immunogenic mechanisms for defeating cancer and infectious disease | Health Technology |
Roche Labs |
